Given the anti-inflammatory effects of ABA in neuroinflammation and Alzheimer’s disease in combination with its capacity to activate PPARγ, we hypothesized that ABA could improve remyelination through modulation of macrophage phenotype and neuroinflammation in experimental models of MS. The gene discussed is PPARG; the disease is early-onset autosomal dominant Alzheimer disease.